KOD Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 7.47%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

Kodiak Sciences, Inc. has a consensus price target of $29.00, signalling upside risk potential of 13.02%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 17.78%. Given that Arcutis Biotherapeutics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Arcutis Biotherapeutics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.667, which suggesting that the stock is 166.742% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.710, suggesting its more volatile than the S&P 500 by 70.962%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 10.57x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -15814.98%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Cytokinetics, Inc.'s return on equity of --.

Kodiak Sciences, Inc. has a consensus price target of $29.00, signalling upside risk potential of 13.02%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $89.44 which suggests that it could grow by 41.55%. Given that Cytokinetics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Cytokinetics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.667, which suggesting that the stock is 166.742% more volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.718%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Cytokinetics, Inc. quarterly revenues of $1.9M. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 86.23x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 10.24%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Kodiak Sciences, Inc. has a consensus price target of $29.00, signalling upside risk potential of 13.02%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Kodiak Sciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Amicus Therapeutics, Inc..

Kodiak Sciences, Inc. has a beta of 2.667, which suggesting that the stock is 166.742% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -82.06%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Kodiak Sciences, Inc. has a consensus price target of $29.00, signalling upside risk potential of 13.02%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 11.94%. Given that Kodiak Sciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Kodiak Sciences, Inc. has a beta of 2.667, which suggesting that the stock is 166.742% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 13.79x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.